Limits...
Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer.

Chen B, Liu L, Xu H, Yang Y, Zhang L, Zhang F - Exp Ther Med (2015)

Bottom Line: Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05).The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05).In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu 215000, P.R. China.

ABSTRACT

The aim of this study was to compare the immune function of patients with cervical cancer and the cancer recurrence rate in patients treated with biological immune therapy combined with chemotherapy or with chemotherapy only. A total of 79 postoperative patients with cervical cancer participated in the present study. They were randomly divided into a control group and an experimental group. Patients in the control group were treated with cisplatin chemotherapy. Patients in the experimental group were treated with dendritic cell-cytokine-induced killer (DC-CIK) cells combined with cisplatin chemotherapy. The CD3(+), CD4(+), CD8(+), CD16(+), CD56(+) and CD4(+)CD25(+) cell ratios in peripheral blood, and the expression levels of perforin, granzyme B (GraB) and CD107a of peripheral blood mononuclear cells (PBMCs) in all patients prior to and following treatment were observed. The changes of immune function and recurrence rate between these two groups prior to and following treatment were compared. Prior to treatment, the lymphocyte ratio had no significant difference between the two groups (P>0.05). Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05). The positive expression levels of perforin, GraB and CD107a of PBMCs in the experimental group following treatment were significantly higher than those prior to treatment and those of the control group (P<0.05). The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05). In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.

No MeSH data available.


Related in: MedlinePlus

Comparison of the cumulative (A) recurrence rate and (B) survival rate between the control and experimental groups. *P<0.05 represents a significant difference.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4316956&req=5

f3-etm-09-03-1063: Comparison of the cumulative (A) recurrence rate and (B) survival rate between the control and experimental groups. *P<0.05 represents a significant difference.

Mentions: Patients from the two groups were followed up for more than 3 years after treatment. Eighteen recurrent cases were found in the control group but only nine recurrent cases were found in the experimental group. Kaplan-Meier curves demonstrated that the cumulative 1-year, 2-year and 3-year recurrence rates in the control group were 28.2% (11 cases), 35.9% (14 cases) and 46.2% (18 cases), respectively. In the experimental group, the cumulative recurrence rates were 5% (2 cases), 15% (6 cases) and 22.5% (9 cases), respectively. The cumulative recurrence rates between the control and experimental groups were significantly different when compared by log-rank test (P<0.05). The cumulative 1-year, 2-year and 3-year survival rates in the control group were 92.31, 76.92 and 56.41%, respectively. In the experimental group, the cumulative survival rates were 97.25, 90 and 80%, respectively. Log-rank test showed that the cumulative survival rate of the experimental group was significantly different from that of the control group (P<0.05; Fig. 3).


Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer.

Chen B, Liu L, Xu H, Yang Y, Zhang L, Zhang F - Exp Ther Med (2015)

Comparison of the cumulative (A) recurrence rate and (B) survival rate between the control and experimental groups. *P<0.05 represents a significant difference.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4316956&req=5

f3-etm-09-03-1063: Comparison of the cumulative (A) recurrence rate and (B) survival rate between the control and experimental groups. *P<0.05 represents a significant difference.
Mentions: Patients from the two groups were followed up for more than 3 years after treatment. Eighteen recurrent cases were found in the control group but only nine recurrent cases were found in the experimental group. Kaplan-Meier curves demonstrated that the cumulative 1-year, 2-year and 3-year recurrence rates in the control group were 28.2% (11 cases), 35.9% (14 cases) and 46.2% (18 cases), respectively. In the experimental group, the cumulative recurrence rates were 5% (2 cases), 15% (6 cases) and 22.5% (9 cases), respectively. The cumulative recurrence rates between the control and experimental groups were significantly different when compared by log-rank test (P<0.05). The cumulative 1-year, 2-year and 3-year survival rates in the control group were 92.31, 76.92 and 56.41%, respectively. In the experimental group, the cumulative survival rates were 97.25, 90 and 80%, respectively. Log-rank test showed that the cumulative survival rate of the experimental group was significantly different from that of the control group (P<0.05; Fig. 3).

Bottom Line: Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05).The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05).In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu 215000, P.R. China.

ABSTRACT

The aim of this study was to compare the immune function of patients with cervical cancer and the cancer recurrence rate in patients treated with biological immune therapy combined with chemotherapy or with chemotherapy only. A total of 79 postoperative patients with cervical cancer participated in the present study. They were randomly divided into a control group and an experimental group. Patients in the control group were treated with cisplatin chemotherapy. Patients in the experimental group were treated with dendritic cell-cytokine-induced killer (DC-CIK) cells combined with cisplatin chemotherapy. The CD3(+), CD4(+), CD8(+), CD16(+), CD56(+) and CD4(+)CD25(+) cell ratios in peripheral blood, and the expression levels of perforin, granzyme B (GraB) and CD107a of peripheral blood mononuclear cells (PBMCs) in all patients prior to and following treatment were observed. The changes of immune function and recurrence rate between these two groups prior to and following treatment were compared. Prior to treatment, the lymphocyte ratio had no significant difference between the two groups (P>0.05). Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05). The positive expression levels of perforin, GraB and CD107a of PBMCs in the experimental group following treatment were significantly higher than those prior to treatment and those of the control group (P<0.05). The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05). In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.

No MeSH data available.


Related in: MedlinePlus